Concerns over use of hydroxyethyl starch solutions.
Department of Anaesthesiology and Intensive Care Medicine, Centre for Sepsis Care and Control, Jena University Hospital, D-07747 Jena, Germany.
Christiane S
CS
Hartog
Critical Care Medicine Department, National Institutes of Health, Bethesda, MD 20892, USA.
Charles
C
Natanson
Critical Care Medicine Department, National Institutes of Health, Bethesda, MD 20892, USA.
Junfeng
J
Sun
Department of Transfusion Medicine, National Institutes of Health, Bethesda.
Harvey G
HG
Klein
Department of Anaesthesiology and Intensive Care Medicine, Centre for Sepsis Care and Control, Jena University Hospital, D-07747 Jena, Germany konrad.reinhart@med.uni-jena.de.
Konrad
K
Reinhart
D001778:Blood Coagulation Disorders / Q000139:chemically induced; D016638:Critical Illness / Q000628:therapy; D019317:Evidence-Based Medicine / Q000592:standards; D006474:Hemorrhagic Disorders / Q000139:chemically induced; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000009:adverse effects* / Q000627:therapeutic use; D020896:Hypovolemia / Q000188:drug therapy; D020300:Intracranial Hemorrhages / Q000139:chemically induced; D007880:Legislation, Drug; D010952:Plasma Substitutes / Q000009:adverse effects* / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000139:chemically induced; D012307:Risk Factors; D018805:Sepsis / Q000628:therapy; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration
D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes